August 27, 2013
bioTheranostics Appoints Three Key Executives
Appointments strengthen management team as company expands its commercialization efforts and launches Breast Cancer IndexSM molecular test
FOR IMMEDIATE RELEASE…Aug. 27, 2013…SAN DIEGO…bioTheranostics, Inc., a leading provider of molecular diagnostic solutions for metastatic cancer, today announced the addition of three industry veterans to its senior management team as it prepares for further commercial expansion and launch of its Breast Cancer IndexSM (BCI) molecular test. Gail Sloan joins the company as chief financial officer, Macey Johnson, III, as vice president of managed care and reimbursement, and Matt Sargent as Breast Cancer Index commercialization leader.
Richard Ding, president and CEO of bioTheranostics, said, “It is an honor to welcome Gail, Macey, and Matt. Their wealth of experience in finance, oncology molecular diagnostics, reimbursement, managed care, and sales and business leadership will be instrumental as we expand the commercial reach of our proprietary solutions for metastatic cancers and increase our partnerships with payors to make our high-value diagnostic tests more broadly available to cancer patients and their physicians. We look forward to this important next stage in the evolution of bioTheranostics.”
Sloan joins bioTheranostics with nearly 16 years of financial experience at publicly traded life sciences companies. She was chief financial officer and vice president of finance at La Jolla Pharmaceutical, playing a key role in raising more than $330 million through multiple private placements and public offerings. Sloan also was assistant controller at Affymax Research Institute, where she helped lead the spinoff of subsidiary Affymetrix, a manufacturer of DNA microarrays. Sloan started her finance career at Ernst ∓ Young. She is a certified public accountant and earned her bachelor’s degree in business from California Polytechnic State University, San Luis Obispo.
Johnson brings nearly 25 years of biologics and diagnostics experience to bioTheranostics, including positions at Genomic Health and Genentech. He has served in field management, managed care, government affairs, and managed care marketing capacities, successfully launching industry-leading oncology therapeutics Avastin, Herceptin, and Tarceva. At Genomic Health, he developed managed care messaging and strategy for its molecular assays. Johnson holds a master’s degree in business administration from Manderson Graduate School of Business at The University of Alabama.
Sargent has more than 16 years of life sciences experience, with a strong focus in molecular oncology diagnostics. He most recently was vice president of oncology sales for Caris Life Sciences, where he built and trained the oncology sales team, resulting in significant sales growth. He also has held senior sales and marketing leadership positions at MedTrust Online, and Exiqon Diagnostics (formerly Oncotech). He received a bachelor’s degree in anatomy and animal physiology from Cornell University, a master’s degree in cancer physiology from the University at Buffalo, and a master’s degree in business administration from Pepperdine University.
The prospective comparison study was conducted by researchers at Massachusetts General Hospital, Queen Mary University and Royal Marsden Hospital in London, the University of Otago in New Zealand, and bioTheranostics. They looked at tumor samples from 665 postmenopausal women with ER-positive breast cancer enrolled in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical trial. The samples had previously been tested by the 21-gene recurrence score and IHC4. BCI analysis was conducted, and researchers assessed the ability of the BCI to predict 10-year risk of recurrence, comparing it to the 21-gene recurrence scores and IHC4. They also tested the ability of the assays specifically to predict early and late distant recurrence beyond standard clinicopathological variables.
Findings show that all assays had significant ability to predict early distant recurrence, but only BCI predicted late distant recurrence. For late recurrence, only 3.5 percent of women in the lowrisk group based on BCI results experience recurrence of their breast cancer, compared with 15.4 percent in the high-risk group. To access the study, click here.
bioTheranostics, Inc., is the leading solution provider for metastatic cancer management, leveraging its unique expertise in gene expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAPaccredited diagnostic laboratory to perform its proprietary tests: the CancerTYPE ID® molecular classification test; PRÉCIS® Precision Medicine, which includes biomarker profiles for non-small cell lung, colorectal, and other cancers; and Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptor-positive, lymph node-negative breast cancer. bioTheranostics, a bioMérieux company, is based in San Diego. Learn more at www.biotheranostics.com.